Research programme: vaccines - Bharat Biotech

Drug Profile

Research programme: vaccines - Bharat Biotech

Alternative Names: BBV 121; Malaria vaccine - Bharat Biotech; Methicillin-resistant Staphylococcus aureus vaccine - Bharat Biotech; Non-typhoidal salmonella vaccine -Bharat Biotech; NTS conjugate vaccine - Bharat Biotech; Papilloma virus vaccine - Bharat Biotech; Pertussis vaccine - Bharat Biotech; PvR II; Tetanus vaccine - Bharat Biotech; Zika inactivated vaccine - Bharat Biotech; Zika recombinant vaccine - Bharat Biotech; Zika virus vaccine - Bharat Biotech; ZikaVac

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bharat Biotech
  • Developer Bharat Biotech; Center for Vaccine Development
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Duffy antigen binding protein modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Zika virus infection
  • No development reported Human papillomavirus infections; Malaria; Methicillin-resistant Staphylococcus aureus infections; Pertussis; Salmonella infections; Tetanus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in India (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in India (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for research development in Human-papillomavirus-infections in India (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top